M&A Deal Summary

Athenex Acquires Kuur Therapeutics

On May 4, 2021, Athenex acquired life science company Kuur Therapeutics for 185M USD

Acquisition Highlights
  • This is Athenex’s 2nd transaction in the Life Science sector.
  • This is Athenex’s largest (disclosed) transaction.
  • This is Athenex’s 1st transaction in the United Kingdom.

M&A Deal Summary
Date 2021-05-04
Target Kuur Therapeutics
Sector Life Science
Buyer(s) Athenex
Deal Type Add-on Acquisition
Deal Value 185M USD

Target

Kuur Therapeutics

London, United Kingdom
Kuur Therapeutics is a developer, manufacturer, and marketer of cellular immunotherapy products for the treatment of cancer and infections. Kuur Therapeutics’s lead oncology product, baltaleucel-T, is aimed at a range of cancers associated with the oncogenic Epstein Barr virus (EBV), including non-Hodgkin lymphomas, Hodgkin lymphoma, and nasopharyngeal carcinoma. Kuur Therapeutics is based in London, United Kingdom.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Athenex

Buffalo, New York, United States
Category Company
Founded 2003
Sector Life Science
Employees652
Revenue 120M USD (2021)
DESCRIPTION

Athenex is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer. Athenex has organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform, and a Global Supply Chain Platform. The Company’s current clinical pipeline is derived from four different platform technologies: (1) Orascovery, based on P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) Cell therapy, and (4) Arginine deprivation therapy. Athenex was founded in 2003 and is based in Buffalo, New york.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Add-on Acquisition) 2 of 2
Country (United Kingdom) 1 of 1
Year (2021) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-09-09 QuaDPharma

New York, New York, United States

QuaDPharma specializing in pharmaceutical manufacturing, analytical, and support services to the pharmaceutical and biotech industries.

Buy -
Mergr

Product

Company

Legal